<DOC>
	<DOC>NCT00873639</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoRapid® (insulin aspart) and Levemir® (insulin detemir) after switch from human insulins for treatment of type 1 diabetes under normal clinical practice conditions in Romania.</brief_summary>
	<brief_title>Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Any subject with type 1 diabetes who is treated with human rapid and intermediate (NPH) insulin in basalbolus regimen Subjects currently being treated with insulin aspart and insulin detemir Subjects who were previously enrolled in this study Subjects with a hypersensitivity to insulin aspart or to any of the excipients Subjects with a hypersensitivity to insulin detemir or to any of the excipients Women who are pregnant or have the intention of becoming pregnant within next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>